Clinical Trial Update: Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma [Phase 1]

View source ↗

Summary

This update covers a Phase 1 trial of sorafenib in patients with recurrent or progressive malignant glioma, including several glioma subtypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Gliosarcoma
• Malignant Glioma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Status: COMPLETED